When there are several drugs or types of drugs available,
When there are several drugs or types of drugs available, doctors usually first prescribe the one with the fewest side effects and/or the one that is least disruptive to the normal functioning of the body. If the less-invasive drug doesn't work, then they switch to other drugs. Those heavily-advertised drugs that are immune-system disruptors and have as their side effects cancer, inflammatory bowel disease, serious infections, etc., and which are administered by injection-- those drugs are much less likely to be prescribed as the first-line treatment than a drug that can be taken orally and has lesser side effects.
I also note that one of those drugs says that it starts working in 4 months. This VERY PRELIMINARY Prurisol study found that it worked within weeks.
Also remember: not only is Prurisol an oral medication rather than administered by injection, but so far the side effect seem to be less. Here's the thing we don't know:
Is this a CURE rather than a treatment? It seemed to be a cure in the mice, but the mice didn't survive long enough after the trial to know whether the psoriasis comes back after awhile.
In any case, a treatment that makes the psoriasis go away for some period of time, which means the person could go off the medication, is certainly preferable to a treatment that requires constant dosing, like Humira and Taltz.
2
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
RedMane and South Dakota DSS: A New Milestone Talk about a leap into the digital age. South Dakota's Department of Social Services, teaming up with RedMane Technology, has just rolled out the Child Care Assistance Program on their BEES platform. That’s Benefits Eligibility and Enrollment System for those not keeping track. It represents a significant step in making life...
Continue Reading
Hexaware Registers Revenue Growth Amid EBIT Challenges Hexaware Technologies (NSE: HEXT) just dropped their Q3 numbers like a heavyweight fighter showing off new moves—and boy, there's plenty to chew on. Revenue hit $411.9 million, a decent 4.3% climb from last year. But dig deeper and you'll find some bruises hiding under that revenue glow: EBIT took a 13.5% yearly...
Continue Reading
Another Day, Another Data Breach It seems like you can’t throw a stone without hitting a data breach these days—and this time, it’s Lumara Bio USA’s turn under the spotlight. The Princeton-based oncology therapeutics outfit, part of Germany’s ITM Isotope Technologies, spilled some beans it never meant to. We're talking some pretty sensitive stuff here, folks....
Continue Reading
Shifting Gears at Ameritas: New VP Takes the Helm Well, chalk one up for Ameritas on this move. They've just brought on Ying Zhao as the new vice president of actuarial and financial strategy. It's a mouthful of a title, sure, but it's the role itself that's worth watching. Ameritas, for those not tracking, is a major player in the insurance and financial universe, doing...
Continue Reading
The Legal Rigmarole The market's got its knickers in a twist over AST SpaceMobile, folks. If you've been dabbling in NASDAQ:ASTS between March '25 and mid-July '26, it's time to perk up those ears. The legal eagles at Robbins Geller Rudman & Dowd LLP are rallying the troops for a class action lawsuit with you front and center. Deadline's looming on November 13, 2026, for...
Continue Reading
Trick or Treat the Safe Way Ah, Halloween. A time when you don't just get to pretend to be someone else; you get to pile on the candy like it's a second job. But hold up! Before your pint-sized Dracula sprints into the foggy night, heed some wisdom from the folks at Allegheny Health Network. They aren't just offering another bowl of sugar-coated advice; they've got...
Continue Reading
A Key Milestone for Bridge Legal Here's a juicy tidbit for you: Bridge Legal is shaking things up by promoting Randi Cruz to Chief Financial Officer. It's a big deal, folks, especially when you consider that this company is one of those movers and shakers in the legal tech world. Randi's journey at Bridge Legal hasn't been a walk in the park, but more of a strategic...
Continue Reading
It seems the digital world and power supply have locked in a new dance as DayOne Data Centers teams up with Sembcorp Utilities. It's high time we gave this story a solid look, especially with data centers gobbling energy faster than my old trading partner downs an espresso. Tackling Energy Constraints Head-On The digital infrastructure beast is hungry for power, and...
Continue Reading
Bracing For Impact: The Tough Truth About West Fraser's Recent Moves Things are looking a bit bleak over at West Fraser Timber Co. They've just dropped their Q3 2026 results, ringing the bell with a hefty $80 million loss. As if that wasn't enough, the company's decided to indefinitely curtail a couple of mills—one in Lanett, Alabama and the other in Leola, Arkansas....
Continue Reading
Hope Charities Takes a Stand for Patients In Prairieville, Hope Charities is throwing its weight behind a bill they believe is brewing up a patient revolution. The Patients Choice in Specialty Pharmacy Act, otherwise known as H.R. 10549, sparked by Representatives Neal Dunn and Joe Wilson, tackles the comfortable partnerships some insurers have been enjoying with their...
Continue Reading
Top 5 Most Recently Viewed Articles
Citius Oncology's Latest Financial Move Citius Oncology, Inc. is making significant strides in the oncology space with its recent announcement regarding a financing initiative worth approximately $9 million. The company, which specializes in pioneering cancer treatments, has entered into a securities purchase agreement with an institutional investor to facilitate a...
Continue Reading
Marex Group plc Class Action Update for Interested Investors Attention to all investors in Marex Group plc (NASDAQ: MRX), a significant announcement has surfaced regarding a class action lawsuit that may have implications for shareholders. The firm of Levi & Korsinsky, LLP has notified stakeholders about legal proceedings aimed at addressing potential losses incurred due...
Continue Reading
Introduction to the Methode Electronics Case In a significant development within the financial and legal sectors, investors in Methode Electronics, Inc. are being encouraged to lead a securities fraud class action lawsuit. This situation has arisen due to substantial losses experienced by shareholders during a particular class period. Class Period and Its Implications The...
Continue Reading
NEST: Bridging the Gap in Youth Entrepreneurship In the hustle of Atlanta, there's a nonprofit doing something that makes you sit up and take notice. We're talking about NEST—New Entrepreneurs Shaping Tomorrow. It's not just a fancy name; it's a mission. They’re arming students, who would otherwise be flying blind in the business world, with the financial education...
Continue Reading
The Incredible Journey of Curtiss-Wright Stock Curtiss-Wright Corporation (NYSE: CW) has shown impressive performance over the past 15 years, beating the market averages by 8.53% each year, resulting in an average annual return of 20.86%. With a market capitalization nearing $20.03 billion, it's evident that this company has made quite a mark on investors’ portfolios....
Continue Reading